Abstract
REPORT DESCRIPTION
H1N1 Influenza A (2009) is the first pandemic influenza of 21st century
affecting more than more than four lac people in more than 180 countries
across the globe in 2009. The flu broke in Mexico in the month of March and
then affected U.S. and after that it spread across the globe. H1N1 (2009)
influenza have a mutation of pig, bird and humans which has made it more
dangerous and fatal compared to previous occurrence of H1N1 (1918).
The pandemic outbreak of the influenza opened the gates for the drugs such as
Tamiflu in the initial phase for the curing of the disease but the following
phase will see a shift from curing to prevention. Thus, arise the requirement
for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast
for the upcoming vaccines for the prevention of the disease among the
unaffected population. The vaccines market is classified for the intramuscular
vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market
revenues and the remaining will be tapped by the intranasal vaccines. The
initial lot of vaccines will be of egg based and cell based manufacturing. The
market forecast is from late 2009 as the first lot of doses are expected to be
rolled out in the first week of October 2009.
The first movers of the in the vaccines market are Glaxo Smith Kline (GSK),
Novartis, CSL, Medimmune, Baxter, Sinovec and Sanofi Pastuer. Medimmune is the
only producer of the intranasal vaccine whereas other companies are expected
to come out with intramuscular vaccines. The companies have got approvals for
their first lots from the governments of the various countries such as U.S.,
U.K., France, China, Denmark and Australia. The involvement of government
bodies, increased awareness about prevention and pandemic situation of the
influenza is driving the market for the vaccines.
Due to intensive ongoing research and technology introduction, the market
players are compelled to understand the market dynamics, innovations,
pricing, products, marketing and regulatory framework of the market.
The global H1N1 Influenza vaccine market is estimated to be of 676 million in
2009 with first lot of doses being commercialized on 30th September' 2009. The
market will see a high CAGR for the next two years i.e. the market is expected
to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011.
However, the very high CAGR will settle down by 2012 to 30% for the period of
2009 to 2012. The reason for the sudden settle down of the growth is that it
is expected that most of the world population will be immunized by the end of
2011.
Market estimates and forecast
This report will enable strategic understanding and opportunities in the H1N1
2009 influenza vaccines market. The report covers the following market
segments.
| 
View Cart
